Lead optimization of a therapeutic candidate for alzheimer's disease
Active Project Grant Awarded Last action
- Award ID
- R43AG090243
- Recipient
-
Stress Therapeutics, Inc. UEI VLU8DHDM9JZ3
- Awarding agency
-
National Institute on Aging
National Institutes of Health, Department of Health and Human Services
- Obligated
- $349,605
Award facts
- Assistance listing
- 93.866 Aging Research
- Completion date 72% complete
- Originally
- Place of performance
- California, USA
Award details come from USAspending.gov.
Description
- Abstract
- Overactivation of the hypothalamic-pituitary-adrenal (HPA) axis occurs in alzheimer's disease (ad) and dysregulation of the stress system plays a mechanistic role in the pathophysiology of ad progression. This phase I sbir proposal will set the groundwork for the clinical development of a first-in-class treatment for the long-term management for ad and other conditions characterized by excessive activation of the HPA. While the stress response is essential for survival, IT can become dysregulated. Excessive activation of the HPA axis results in increased glucocorticoids release, which has detrimental actions on the central nervous system, causing hippocampal and prefrontal cortex functional impairments, and contributes to ad progression. Therapeutics to modulate the HPA axis have been under research for decades. While glucocorticoid receptor antagonists have shown some potential in the treatment of depression, they can be counterproductive when used long-term. CRF receptor type 1 (CRF1) antagonists have also been studied extensively but have generally been unsatisfactory due to side effects and limited efficacy on the HPA. Brain-penetrant CRF1 antagonists can induce fear and aversion in humans, which may represent class side effects. Thus, there is a considerable unmet medical need for identification of novel therapeutics to normalize HPA hyperactivity that are effective and tolerable for long-term use. HPA hyperactivity is believed to be a key pathogenic driver of ad and a validated therapeutic target. The present phase I sbir seeks to advance the development of a novel therapeutic to reduce HPA hyperactivity and will lay the foundations for the clinical development of a first-in-class therapeutic by optimizing a lead candidate therapeutic for the long-term management of chronic hyperactivity of the hypothalamic pituitary adrenal axis (HPA) for ad and other degenerative conditions.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Original award | $349,605 |
Quick answers
Who received award R43AG090243?
R43AG090243 was awarded to Stress Therapeutics, Inc. by National Institute on Aging (National Institutes of Health) on June 1, 2025.
How much is award R43AG090243 worth?
$349,605 has been obligated on R43AG090243.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award